S. Durán‐García

1.3k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

S. Durán‐García is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, S. Durán‐García has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 8 papers in Molecular Biology. Recurrent topics in S. Durán‐García's work include Diabetes Treatment and Management (12 papers), Diabetes Management and Research (11 papers) and Pancreatic function and diabetes (9 papers). S. Durán‐García is often cited by papers focused on Diabetes Treatment and Management (12 papers), Diabetes Management and Research (11 papers) and Pancreatic function and diabetes (9 papers). S. Durán‐García collaborates with scholars based in Spain, United States and Germany. S. Durán‐García's co-authors include Stefano Del Prato, Michael A. Nauck, Shamik Parikh, Katja Rohwedder, M. Elze, Juris J. Meier, Laura Maffei, Hannele Yki‐Järvinen, Sandra Thiemann and Sanjay Patel and has published in prestigious journals such as Diabetes Care, Diabetes and Endocrinology.

In The Last Decade

S. Durán‐García

19 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

2011 427 citations Michael A. Nauck, Stefano Del Prato et al. Diabetes Care profile →

Peers

S. Durán‐García

EDM

MB

SURGE

PHARM

OG

Lorena Mosso Chile

M. T. Chau China

Elisabetta Mandosi Italy

Julie Derving Karsbøl Denmark

Louise Greenberg United States

Shelley A. Klemm Australia

Ivano Franzetti Italy

Ilan Yanuv Israel

Aliza Rozenberg Israel

Ludwig Merker Germany

Lorena Mosso Chile

S. Durán‐García

2.1k ×2.2

EDM

253 ×0.5

MB

1.6k ×3.6

SURGE

140 ×0.7

PHARM

39 ×0.4

OG

Citations per year, relative to S. Durán‐García S. Durán‐García (= 1×) peers Lorena Mosso

Countries citing papers authored by S. Durán‐García

Since Specialization

Citations

This map shows the geographic impact of S. Durán‐García's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Durán‐García with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Durán‐García more than expected).

Fields of papers citing papers by S. Durán‐García

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Durán‐García. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Durán‐García. The network helps show where S. Durán‐García may publish in the future.

Co-authorship network of co-authors of S. Durán‐García

This figure shows the co-authorship network connecting the top 25 collaborators of S. Durán‐García. A scholar is included among the top collaborators of S. Durán‐García based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Durán‐García. S. Durán‐García is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Roussel, Ronan, S. Durán‐García, Yilong Zhang, et al.. (2018). Efficacy and Safety of Continuing Sitagliptin when Initiating Insulin Therapy in Subjects with Type 2 Diabetes Mellitus. Diabetes. 67(Supplement_1). 1 indexed citations

2.

Roussel, Ronan, S. Durán‐García, Yilong Zhang, et al.. (2018). Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study. Diabetes Obesity and Metabolism. 21(4). 781–790. 15 indexed citations

3.

Wolffenbuttel, Bruce H. R., L. Van Gaal, S. Durán‐García, & J. Han. (2016). Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 18(8). 829–833. 10 indexed citations

4.

Schernthaner, Guntram, S. Durán‐García, M Hanefeld, et al.. (2015). Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obesity and Metabolism. 17(7). 630–638. 53 indexed citations

5.

Durán‐García, S., Hannele Yki‐Järvinen, Julio Rosenstock, et al.. (2015). Efficacy and safety of linagliptin as add‐on therapy to basal insulin and metformin in people with Type 2 diabetes. Diabetic Medicine. 33(7). 926–933. 6 indexed citations

6.

Prato, Stefano Del, Michael A. Nauck, S. Durán‐García, et al.. (2015). Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity and Metabolism. 17(6). 581–590. 181 indexed citations

7.

Nauck, Michael A., Stefano Del Prato, S. Durán‐García, et al.. (2014). Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obesity and Metabolism. 16(11). 1111–1120. 93 indexed citations

8.

Hod, Moshe, Elisabeth R. Mathiesen, Lois Jovanovič, et al.. (2013). A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. The Journal of Maternal-Fetal & Neonatal Medicine. 27(1). 7–13. 64 indexed citations

9.

Nauck, Michael A., Stefano Del Prato, Jasmin Meier, et al.. (2013). Vergleich von Dapagliflozin und Glipizid als Add-on-Therapie bei Typ-2-Diabetikern mit unzureichender Blutzuckerkontrolle unter Metformin. DMW - Deutsche Medizinische Wochenschrift. 138(S 01). S6–S16. 6 indexed citations

10.

Yki‐Järvinen, Hannele, Julio Rosenstock, S. Durán‐García, et al.. (2013). Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. Diabetes Care. 36(12). 3875–3881. 117 indexed citations

11.

Nauck, Michael A., Stefano Del Prato, Jasmin Meier, et al.. (2013). [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].. DMW - Deutsche Medizinische Wochenschrift. 138 Suppl 1(1). S6–15. 12 indexed citations

12.

Hod, Moshe, Elisabeth R. Mathiesen, Lois Jovanovič, et al.. (2013). A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. The Journal of Maternal-Fetal & Neonatal Medicine. 1–30. 1 indexed citations

13.

Yki‐Järvinen, Hannele, S. Durán‐García, Sabine Pinnetti, et al.. (2012). Efficacy and Safety of Linagliptin as Add-on Therapy to Basal Insulin in Patients With Type 2 Diabetes. Canadian Journal of Diabetes. 36(5). S39–S39. 9 indexed citations

14.

Nauck, Michael A., Stefano Del Prato, Juris J. Meier, et al.. (2011). Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. Diabetes Care. 34(9). 2015–2022. 427 indexed citations breakdown →

15.

Heller, Simon, Peter Damm, Henriette Mersebach, et al.. (2009). Hypoglycemia in Type 1 Diabetic Pregnancy. Diabetes Care. 33(3). 473–477. 47 indexed citations

16.

Durán‐García, S., et al.. (1981). Specific uptake of human growth hormone by the liver of severely hypothyroid rats. Journal of Endocrinological Investigation. 4(1). 119–123. 4 indexed citations

17.

Durán‐García, S., Marı́a-Jesús Obregón, Gabriella Morreale de Escobar, & Francisco Escobar del Rey. (1981). Differential Effects of Hypothyroidism on the Specific Uptake of Growth Hormone and Prolactin by the Rat Liver*. Endocrinology. 108(6). 2054–2059. 7 indexed citations

18.

Durán‐García, S., et al.. (1981). Insulin receptor interaction in human placental plasma membranes.. PubMed. 37(3). 269–76. 3 indexed citations

19.

Durán‐García, S., et al.. (1979). EFFECTS OF THYROID HORMONES ON LIVER BINDING SITES FOR HUMAN GROWTH HORMONE, AS STUDIED IN THE RAT*. Clinical Endocrinology. 11(3). 275–289. 18 indexed citations

20.

Rosselin, G, D. Bataille, Marc Laburthe, & S. Durán‐García. (1975). [Heterogeneity of protein hormones in radioimmunoassay].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 23(10). 793–803.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact